Raymond James & Associates’s Quantum Biopharma Class B Subordinate Voting Shares QNTM Stock Holding History

Raymond James & Associates’s Portfolio QNTM Stock Details QNTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-231	Closed	-$12K	–	4159
2022 Q2	$12K	Hold	231	–	–	﹤0.01%	3928
2022 Q1	$13K	Hold	231	–	–	﹤0.01%	4051
2021 Q4	$16K	Hold	231	–	–	﹤0.01%	4046
2021 Q3	$24K	Hold	231	–	–	﹤0.01%	3991
2021 Q2	$26K	Hold	231	–	–	﹤0.01%	3965
2021 Q1	$29K	Buy	+231	New	+$32.3K	﹤0.01%	3897

Other funds holding QNTM

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Wolverine Trading Chicago, Illinois $139B AUM 31.83% 1-Year Est. Return

Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

Raymond James & Associates's QNTM Position: Q3 2022 in Review

Raymond James & Associates sold out of Quantum Biopharma Class B Subordinate Voting Shares (QNTM) in Q3 2022, closing a stake of 231 shares — an estimated $12K sold.

Raymond James & Associates first reported a position in QNTM in Q1 2021 and held it in 6 quarters. The position peaked at $29K in Q1 2021. 15 funds tracked by Wall St. Rank hold QNTM as of Q3 2022.

Raymond James & Associates reported no remaining Quantum Biopharma Class B Subordinate Voting Shares position as of Q3 2022 after selling out during the quarter.
Raymond James & Associates sold 231 Quantum Biopharma Class B Subordinate Voting Shares shares in Q3 2022, an estimated $12K.
Raymond James & Associates first reported a position in Quantum Biopharma Class B Subordinate Voting Shares in Q1 2021 and held it in 6 quarters.
Raymond James & Associates's Quantum Biopharma Class B Subordinate Voting Shares position peaked at $29K in Q1 2021.
15 funds tracked by Wall St. Rank held Quantum Biopharma Class B Subordinate Voting Shares as of Q3 2022.

Based on Raymond James & Associates's 13F filing for Q3 2022, filed 25 Oct 2022.